GlassScriptPhysician profile
Mary H Brown
NPI 1083178321
$1,328.12
in general payments reported to CMS, 2019-2025
21 companies · $550 in 2025
The $550 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.46 · 2022: $162 · 2023: $212 · 2024: $383 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Education: $47.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.66 |
| Education | $47.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $213.86 | 2024-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $161.09 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $148.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $112.77 | 2023-2025 | Farxiga |
| Amgen INC. | $111.52 | 2024-2025 | Aranesp, Parsabiv, Tavneos |
| Glaxosmithkline, LLC. | $65.02 | 2022-2024 | Benlysta |
| Ardelyx, INC. | $60.17 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $50.33 | 2025 | Tarpeyo |
| Edwards Lifesciences Corporation | $50.11 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mallinckrodt Hospital Products INC. | $49.95 | 2022-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $43.37 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $38.99 | 2022-2025 | Jynarque |
| Akebia Therapeutics INC | $36.92 | 2022-2024 | Vafseo |
| Genzyme Corporation | $33.96 | 2023 | |
| Fresenius USA Marketing, INC. | $31.44 | 2022-2024 | Velphoro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $22.86 | 2023 | Rayaldee |
| Scpharmaceuticals INC. | $22.04 | 2024 | |
| Lilly USA, LLC | $21.75 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.95 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $15.78 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.